<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406106</url>
  </required_header>
  <id_info>
    <org_study_id>2009/001</org_study_id>
    <nct_id>NCT01406106</nct_id>
  </id_info>
  <brief_title>Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia</brief_title>
  <official_title>EFFECT OF PLANT STEROLS ON THE LIPID PROFILE OF PATIENTS WITH HYPERCHOLESTEROLAEMIA. RANDOMISED, EXPERIMENTAL STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gerencia de Atención Primaria, Albacete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación para la Investigación Sanitaria en Castilla-La Mancha (FISCAM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Castilla-La Mancha Health Research Foundation.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gerencia de Atención Primaria, Albacete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background information Studies have been conducted on supplementing the daily diet with plant
      sterol ester-enriched milk derivatives in order to reduce LDL-cholesterol levels and,
      consequently, cardiovascular risk. However, clinical practice guidelines on
      hypercholesterolaemia state that there is not sufficient evidence to recommend their use in
      subjects with hypercholesterolaemia. The null hypothesis establishes that there is no
      relationship between the decrease in blood LDL-cholesterol levels and the consumption of
      stanol ester enriched liquid yoghurt. The alternative hypothesis establishes a relationship
      between such consumption and the incidence of the primary variable.

      The main objective of this study is to determine the efficacy of the intake of 2 g of plant
      sterol esters a day in lowering LDL-cholesterol levels in patients diagnosed with
      hypercholesterolaemia. The specific objectives are: 1) to quantify the efficacy of the daily
      intake of plant sterol esters in lowering LDL-cholesterol, total cholesterol and
      cardiovascular risk in patients with hypercholesterolaemia; 2) to evaluate the occurrence of
      adverse effects of the daily intake of plant sterol esters; 3) to identify the factors that
      determine a greater reduction in lipid levels in subjects receiving plant sterol ester
      supplements.

      Study design Randomised, double-blind, placebo controlled experimental trial carried out at
      family doctors' surgeries at three health centres in the Health Area of Albacete (Spain). The
      study subjects will be adults diagnosed with &quot;limit&quot; or &quot;defined&quot; hypercholesterolaemia and
      who have LDL cholesterol levels of 130 mg/dl or over. A dairy product in the form of liquid
      yoghurt containing 2 g of plant sterol ester per container will be administered daily after
      the main meal, for a period of 24 months. The control group will receive a daily unit of
      yogurt not supplemented with plant sterol esters that has a similar appearance to the
      enriched yoghurt. The primary variable is the change in lipid profile at 1, 3, 6, 12, 18 and
      24 months. The secondary variables are: change in cardiovascular risk, adherence to the dairy
      product, adverse effects, adherence to dietary recommendations, frequency of food
      consumption, basic physical examination data, health problems, lipid-lowering medication,
      physical activity, smoking habits and socio-demographic variables.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Lipid levels will be measured in both plasma and capillary blood at the initial visit. The validity of the capillary blood lipid levels can be checked with the Cardiochek analyser (by total cholesterol, HDL-cholesterol and triglyceride strips, and subsequent calculation of LDL-cholesterol using the Friedewald formula). The measurements at 3, 12 and 24 months will be in plasma. At 1, 6 and 18 months they will only be in capillary blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiovascular risk</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>SCORE and REGICOR tables will be used for the evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the dairy product (liquid yoghurt)</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>By self-report and Morisky-Green scale, which determines the degree of coincidence between the patient's behaviour and the doctor's advice (a non-complier is one who answers one of the four questions of the scale inappropriately).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Considered as any undesirable event in any patient included in the study, even though it does not have a causal relation with the product. Known adverse events of phytosterols in the diet at the proposed doses: occasionally mild digestive alterations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the dietary recommendations</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>5-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of food intake</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Using the CDC-FFQ questionnaire, validated in Spain (Aguirre, 2008) considered appropriate to classify the subjects according to their intake of food and nutrients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiovascular events</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Ischaemic heart disease, atherothrombotic cerebrovascular disease, heart failure and peripheral artery disease.
-Weight, height, body mass index (BMI): classification of subjects according to degree of obesity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight, height, body mass index (BMI)</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Classification of subjects according to degree of obesity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Amount of aerobic exercise (&quot;active&quot; if performs aerobic exercise for 30 minutes or more, three or more times a week, &quot;partially active&quot; if exercises with less frequency and for less time that this and &quot;inactive&quot; when does not perform any type of exercise).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking habit</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Considered smoker if answers yes to the question &quot;do you smoke?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure (two measurements):</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>The result will be the mean of the two measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health problems</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>(WONCA ICPC-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid-lowering pharmacological treatment.</measure>
    <time_frame>At 1, 3, 6, 12, 18 and 24 months</time_frame>
    <description>Whether taking lipid-lowering pharmacological treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-demographic data</measure>
    <time_frame>Initial visit</time_frame>
    <description>Age, gender, marital status, educational level and social class based on occupation (National Classification of Occupations).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Liquid yoghurt with plant stanol esters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).
It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yoghurt without plant stanol esters</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plant stanol esters</intervention_name>
    <description>The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.</description>
    <arm_group_label>Liquid yoghurt with plant stanol esters</arm_group_label>
    <arm_group_label>Yoghurt without plant stanol esters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed with limit hypercholesterolaemia (total cholesterol 200-249 mg/dl)
             or defined hypercholesterolaemia (total cholesterol equal to or above 250 mg/dl) who
             have LDL-cholesterol levels equal to or above 130 mg/dl

          -  Subjects aged 18 years or over attending the participating health centres

          -  Subjects who give their consent to participate after being informed of the study
             objectives

        Exclusion Criteria:

          -  Known hypersensitivity to sterol esters or to the other components of the food that
             contains them (liquid yoghurt)

          -  Contraindication for treatment with sterol esters or any of the components of the food

          -  Physical disability that hinders collaboration

          -  Significant chronic organic or psychiatric disease

          -  Not obtaining informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Párraga, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Unit. Primary Care Head Office of Albacete</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús López-Torres, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Unit. Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Andrés, Bachelor of Computer Sciences</last_name>
    <role>Study Chair</role>
    <affiliation>Research Unit. Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beatriz Navarro, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Unit. Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José María Del Campo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes García-Reyes, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Pilar Galdón, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ángeles Lloret, Bachelor of Pharmacy</last_name>
    <role>Study Chair</role>
    <affiliation>Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Carlos Precioso, Bachelor of Medicine</last_name>
    <role>Study Chair</role>
    <affiliation>Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseba Rabanales, Bachelor of Nursing</last_name>
    <role>Study Chair</role>
    <affiliation>Research Unit. Primary Care Head Office of Albacete.</affiliation>
  </overall_official>
  <reference>
    <citation>Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. [Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies]. Med Clin (Barc). 2005 Apr 30;124(16):606-12. Spanish.</citation>
    <PMID>15871776</PMID>
  </reference>
  <reference>
    <citation>Gutiérrez Fuentes JA, Gómez-Jerique J, Gómez De La Cámara A, Angel Rubio M, García Hernández A, Arístegui I; Diet and Cardiovascular Risk in Spain Study (DRECE II). [Diet and cardiovascular risk in Spain. Description of the evolution of cardiovascular prolile]. Med Clin (Barc). 2000 Dec 2;115(19):726-9. Spanish.</citation>
    <PMID>11141438</PMID>
  </reference>
  <reference>
    <citation>Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367-72.</citation>
    <PMID>8043072</PMID>
  </reference>
  <reference>
    <citation>Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002 Jun 29;324(7353):1570-6. Review.</citation>
    <PMID>12089098</PMID>
  </reference>
  <reference>
    <citation>Keys A. Coronary heart disease, serum cholesterol, and the diet. Acta Med Scand. 1980;207(3):153-60.</citation>
    <PMID>7368981</PMID>
  </reference>
  <reference>
    <citation>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.</citation>
    <PMID>16214597</PMID>
  </reference>
  <reference>
    <citation>McCullough ML, Feskanich D, Stampfer MJ, Giovannucci EL, Rimm EB, Hu FB, Spiegelman D, Hunter DJ, Colditz GA, Willett WC. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr. 2002 Dec;76(6):1261-71.</citation>
    <PMID>12450892</PMID>
  </reference>
  <reference>
    <citation>Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62(16):2333-47. Review.</citation>
    <PMID>12396226</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Trautwein EA, Lapsley KG, Josse RG, Leiter LA, Singer W, Connelly PW. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr. 2005 Feb;81(2):380-7.</citation>
    <PMID>15699225</PMID>
  </reference>
  <reference>
    <citation>Bellisle F, Blundell JE, Dye L, Fantino M, Fern E, Fletcher RJ, Lambert J, Roberfroid M, Specter S, Westenhöfer J, Westerterp-Plantenga MS. Functional food science and behaviour and psychological functions. Br J Nutr. 1998 Aug;80 Suppl 1:S173-93. Review.</citation>
    <PMID>9849358</PMID>
  </reference>
  <reference>
    <citation>Ros E. [Introduction to functional food]. Med Clin (Barc). 2001 May 5;116(16):617-9. Review. Spanish.</citation>
    <PMID>11412648</PMID>
  </reference>
  <reference>
    <citation>Silveira Rodríguez MB, Monereo Megías S, Molina Baena B. [Functional nutrition and optimal nutrition. Near or far?]. Rev Esp Salud Publica. 2003 May-Jun;77(3):317-31. Review. Spanish.</citation>
    <PMID>12852326</PMID>
  </reference>
  <reference>
    <citation>Cater NB. Plant stanol ester: review of cholesterol-lowering efficacy and implications for coronary heart disease risk reduction. Prev Cardiol. 2000 Summer;3(3):121-130.</citation>
    <PMID>11834929</PMID>
  </reference>
  <reference>
    <citation>Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr. 2000 Apr;130(4):767-76.</citation>
    <PMID>10736328</PMID>
  </reference>
  <reference>
    <citation>Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995 Nov 16;333(20):1308-12.</citation>
    <PMID>7566021</PMID>
  </reference>
  <reference>
    <citation>Miettinen TA, Vuoristo M, Nissinen M, Järvinen HJ, Gylling H. Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr. 2000 May;71(5):1095-102.</citation>
    <PMID>10799370</PMID>
  </reference>
  <reference>
    <citation>Noakes M, Clifton PM, Doornbos AM, Trautwein EA. Plant sterol ester-enriched milk and yoghurt effectively reduce serum cholesterol in modestly hypercholesterolemic subjects. Eur J Nutr. 2005 Jun;44(4):214-22. Epub 2004 Aug 17.</citation>
    <PMID>15316827</PMID>
  </reference>
  <reference>
    <citation>Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol. 2000 Jul 1;86(1):46-52.</citation>
    <PMID>10867091</PMID>
  </reference>
  <reference>
    <citation>Nigon F, Serfaty-Lacrosnière C, Beucler I, Chauvois D, Neveu C, Giral P, Chapman MJ, Bruckert E. Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: effect of fibrate treatment. Clin Chem Lab Med. 2001 Jul;39(7):634-40.</citation>
    <PMID>11522112</PMID>
  </reference>
  <reference>
    <citation>Gylling H, Miettinen TA. Combination therapy with statins. Curr Opin Investig Drugs. 2002 Sep;3(9):1318-23. Review.</citation>
    <PMID>12498007</PMID>
  </reference>
  <reference>
    <citation>Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R; Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003 Aug;78(8):965-78. Review.</citation>
    <PMID>12911045</PMID>
  </reference>
  <reference>
    <citation>Law M. Plant sterol and stanol margarines and health. BMJ. 2000 Mar 25;320(7238):861-4.</citation>
    <PMID>10731187</PMID>
  </reference>
  <reference>
    <citation>Mensink RP, Ebbing S, Lindhout M, Plat J, van Heugten MM. Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. Atherosclerosis. 2002 Jan;160(1):205-13.</citation>
    <PMID>11755939</PMID>
  </reference>
  <reference>
    <citation>O'Neill FH, Brynes A, Mandeno R, Rendell N, Taylor G, Seed M, Thompson GR. Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. Nutr Metab Cardiovasc Dis. 2004 Jun;14(3):133-42.</citation>
    <PMID>15330272</PMID>
  </reference>
  <reference>
    <citation>Mattson FH, Grundy SM, Crouse JR. Optimizing the effect of plant sterols on cholesterol absorption in man. Am J Clin Nutr. 1982 Apr;35(4):697-700.</citation>
    <PMID>7072622</PMID>
  </reference>
  <reference>
    <citation>Plat J, van Onselen EN, van Heugten MM, Mensink RP. Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters. Eur J Clin Nutr. 2000 Sep;54(9):671-7.</citation>
    <PMID>11002377</PMID>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.</citation>
    <PMID>11368702</PMID>
  </reference>
  <reference>
    <citation>Van Horn L, Ernst N. A summary of the science supporting the new National Cholesterol Education Program dietary recommendations: what dietitians should know. J Am Diet Assoc. 2001 Oct;101(10):1148-54. Review.</citation>
    <PMID>11678485</PMID>
  </reference>
  <reference>
    <citation>Lichtenstein AH, Deckelbaum RJ. AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation. 2001 Feb 27;103(8):1177-9.</citation>
    <PMID>11222485</PMID>
  </reference>
  <reference>
    <citation>American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006 Jul 4;114(1):82-96. Epub 2006 Jun 19. Erratum in: Circulation. 2006 Dec 5;114(23):e629. Circulation. 2006 Jul 4;114(1):e27.</citation>
    <PMID>16785338</PMID>
  </reference>
  <reference>
    <citation>Algorta Pineda J, Chinchetru Ranedo MJ, Aguirre Anda J, Francisco Terreros S. [Hypocholesteremic effectiveness of a yogurt containing plant stanol esters]. Rev Clin Esp. 2005 Feb;205(2):63-6. Spanish.</citation>
    <PMID>15766477</PMID>
  </reference>
  <reference>
    <citation>Slesinski RS, Turnbull D, Frankos VH, Wolterbeek AP, Waalkens-Berendsen DH. Developmental toxicity study of vegetable oil-derived stanol fatty acid esters. Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 1):227-33.</citation>
    <PMID>10341155</PMID>
  </reference>
  <reference>
    <citation>De Jong N, Pijpers L, Bleeker JK, Ocké MC. Potential intake of phytosterols/-stanols: results of a simulation study. Eur J Clin Nutr. 2004 Jun;58(6):907-19.</citation>
    <PMID>15164112</PMID>
  </reference>
  <reference>
    <citation>Brufau G, Canela MA, Rafecas M. Phytosterols: physiologic and metabolic aspects related to cholesterol-lowering properties. Nutr Res. 2008 Apr;28(4):217-25. doi: 10.1016/j.nutres.2008.02.003. Review.</citation>
    <PMID>19083411</PMID>
  </reference>
  <reference>
    <citation>Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006 Feb;25(1):41-8. Review.</citation>
    <PMID>16522931</PMID>
  </reference>
  <reference>
    <citation>Jordan S, Griffiths J, Pilon K. Sterol and sterolin-containing products: hematologic adverse reactions. CMAJ. 2004 Apr 13;170(8):1347-8, 1351-2. English, French.</citation>
    <PMID>15108714</PMID>
  </reference>
  <reference>
    <citation>Hallikainen MA, Sarkkinen ES, Uusitupa MI. Effects of low-fat stanol ester enriched margarines on concentrations of serum carotenoids in subjects with elevated serum cholesterol concentrations. Eur J Clin Nutr. 1999 Dec;53(12):966-9.</citation>
    <PMID>10602355</PMID>
  </reference>
  <reference>
    <citation>Noakes M, Clifton P, Ntanios F, Shrapnel W, Record I, McInerney J. An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J Clin Nutr. 2002 Jan;75(1):79-86.</citation>
    <PMID>11756063</PMID>
  </reference>
  <reference>
    <citation>Rajaratnam RA, Gylling H, Miettinen TA. Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women. J Am Coll Cardiol. 2000 Apr;35(5):1185-91.</citation>
    <PMID>10758959</PMID>
  </reference>
  <reference>
    <citation>Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study. Nutr Metab Cardiovasc Dis. 2006 Jan;16(1):13-21. Epub 2005 Jul 28.</citation>
    <PMID>16399487</PMID>
  </reference>
  <reference>
    <citation>Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 1999 Apr 6;99(13):1733-9.</citation>
    <PMID>10190884</PMID>
  </reference>
  <reference>
    <citation>Volger OL, Mensink RP, Plat J, Hornstra G, Havekes LM, Princen HM. Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice. Atherosclerosis. 2001 Aug;157(2):375-81.</citation>
    <PMID>11472737</PMID>
  </reference>
  <reference>
    <citation>Ratnayake WM, L'Abbé MR, Mueller R, Hayward S, Plouffe L, Hollywood R, Trick K. Vegetable oils high in phytosterols make erythrocytes less deformable and shorten the life span of stroke-prone spontaneously hypertensive rats. J Nutr. 2000 May;130(5):1166-78.</citation>
    <PMID>10801914</PMID>
  </reference>
  <reference>
    <citation>Child P, Kuksis A. Differential uptake of cholesterol and plant sterols by rat erythrocytes in vitro. Lipids. 1982 Oct;17(10):748-54.</citation>
    <PMID>7176832</PMID>
  </reference>
  <reference>
    <citation>de Jong A, Plat J, Mensink RP. Plant sterol or stanol consumption does not affect erythrocyte osmotic fragility in patients on statin treatment. Eur J Clin Nutr. 2006 Aug;60(8):985-90. Epub 2006 Feb 15.</citation>
    <PMID>16482072</PMID>
  </reference>
  <reference>
    <citation>Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr. 2003 May;57(5):681-92.</citation>
    <PMID>12771969</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ignacio Párraga Martínez</name_title>
    <organization>Gerencia de Atención Primaria de Albacete</organization>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Lipids</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Risks factors</keyword>
  <keyword>Primary Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

